169 related articles for article (PubMed ID: 38583073)
21. Fezolinetant: First Approval.
Lee A
Drugs; 2023 Aug; 83(12):1137-1141. PubMed ID: 37462862
[TBL] [Abstract][Full Text] [Related]
22. Phytoestrogens for menopausal vasomotor symptoms.
Lethaby A; Marjoribanks J; Kronenberg F; Roberts H; Eden J; Brown J
Cochrane Database Syst Rev; 2013 Dec; 2013(12):CD001395. PubMed ID: 24323914
[TBL] [Abstract][Full Text] [Related]
23. Phase II study of fezolinetant for treatment of vasomotor symptoms associated with menopause in Japan.
Takamatsu K; Miki T; Miyazaki K; Hashimoto A; He W; Wang X
Climacteric; 2024 Jun; ():1-9. PubMed ID: 38864290
[TBL] [Abstract][Full Text] [Related]
24. Safety of Fezolinetant for Vasomotor Symptoms Associated With Menopause: A Randomized Controlled Trial.
Neal-Perry G; Cano A; Lederman S; Nappi RE; Santoro N; Wolfman W; English M; Franklin C; Valluri U; Ottery FD
Obstet Gynecol; 2023 Apr; 141(4):737-747. PubMed ID: 36897180
[TBL] [Abstract][Full Text] [Related]
25. Validation and Application of Thresholds to Define Meaningful Change in Vasomotor Symptoms Frequency: Analysis of Pooled SKYLIGHT 1 and 2 Data.
Morga A; Zimmermann L; Valluri U; Siddiqui E; McLeod L; Bender RH
Adv Ther; 2024 Jul; 41(7):2845-2858. PubMed ID: 38775925
[TBL] [Abstract][Full Text] [Related]
26. Black cohosh (Cimicifuga spp.) for menopausal symptoms.
Leach MJ; Moore V
Cochrane Database Syst Rev; 2012 Sep; 2012(9):CD007244. PubMed ID: 22972105
[TBL] [Abstract][Full Text] [Related]
27. Treating moderate-to-severe menopausal vasomotor symptoms with fezolinetant: analysis of responders using pooled data from two phase 3 studies (SKYLIGHT 1 and 2).
Nappi RE; Johnson KA; Stute P; Blogg M; English M; Morga A; Scrine L; Siddiqui E; Ottery FD
Menopause; 2024 Jun; 31(6):512-521. PubMed ID: 38626380
[TBL] [Abstract][Full Text] [Related]
28. Effect of omega-3 supplements on vasomotor symptoms in menopausal women: A systematic review and meta-analysis.
Mohammady M; Janani L; Jahanfar S; Mousavi MS
Eur J Obstet Gynecol Reprod Biol; 2018 Sep; 228():295-302. PubMed ID: 30056356
[TBL] [Abstract][Full Text] [Related]
29. Protocol for systematic review and meta-analysis: hop (Humulus lupulus L.) for menopausal vasomotor symptoms.
Abdi F; Kazemi F; Ramezani Tehrani F; Roozbeh N
BMJ Open; 2016 Apr; 6(4):e010734. PubMed ID: 27105715
[TBL] [Abstract][Full Text] [Related]
30. "Veozah (Fezolinetant): A Promising Non-Hormonal Treatment for Vasomotor Symptoms in Menopause".
Shaukat A; Mujeeb A; Shahnoor S; Nasser N; Khan AM
Health Sci Rep; 2023 Oct; 6(10):e1610. PubMed ID: 37808928
[TBL] [Abstract][Full Text] [Related]
31. FDA approved fezolinetant (Veozah): a critical evaluation of its efficacy and safety for menopausal vasomotor symptoms, calling for prospective research.
Rani P; Zehra D; Mansoor M; Rani P
Arch Womens Ment Health; 2024 Mar; ():. PubMed ID: 38478035
[TBL] [Abstract][Full Text] [Related]
32. Bioidentical hormones for women with vasomotor symptoms.
Gaudard AM; Silva de Souza S; Puga ME; Marjoribanks J; da Silva EM; Torloni MR
Cochrane Database Syst Rev; 2016 Aug; 2016(8):CD010407. PubMed ID: 27479272
[TBL] [Abstract][Full Text] [Related]
33. Neurokinin 1/3 receptor antagonists for menopausal women: A current systematic review and insights into the investigational non-hormonal therapy.
Hassan F; Saleem A; Samuel SS; Sarfraz Z; Sarfraz A; Sarfraz M; Kc M
Medicine (Baltimore); 2023 Jun; 102(23):e33978. PubMed ID: 37335635
[TBL] [Abstract][Full Text] [Related]
34. Fezolinetant: A Potential Treatment for Moderate to Severe Vasomotor Symptoms of Menopause.
DePree B
touchREV Endocrinol; 2023 Nov; 19(2):69-72. PubMed ID: 38187079
[TBL] [Abstract][Full Text] [Related]
35. The efficacy of purified pollen extract for reducing vasomotor symptoms in women: a systematic review and meta-analysis.
Acquarulo EL; Hernandez EC; Kodzodziku F; Nemec EC
Menopause; 2024 Feb; 31(2):154-159. PubMed ID: 38194609
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of gabapentin and pregabalin in patients with vasomotor symptoms: a systematic review and meta-analysis.
Shan D; Zou L; Liu X; Shen Y; Cai Y; Zhang J
Am J Obstet Gynecol; 2020 Jun; 222(6):564-579.e12. PubMed ID: 31870736
[TBL] [Abstract][Full Text] [Related]
37. Neurokinin 3 receptor antagonists for menopausal vasomotor symptoms, an appraisal.
Gompel A; Stuenkel CA
Cell Rep Med; 2023 Jun; 4(6):101076. PubMed ID: 37343519
[TBL] [Abstract][Full Text] [Related]
38. Finding SKYLIGHT for all: fezolinetant efficacy for vasomotor symptoms in subpopulations.
Reed SD
Menopause; 2024 Apr; 31(4):245-246. PubMed ID: 38517209
[No Abstract] [Full Text] [Related]
39. Vasomotor menopausal symptoms and risk of cardiovascular disease: a pooled analysis of six prospective studies.
Zhu D; Chung HF; Dobson AJ; Pandeya N; Anderson DJ; Kuh D; Hardy R; Brunner EJ; Avis NE; Gold EB; El Khoudary SR; Crawford SL; Mishra GD
Am J Obstet Gynecol; 2020 Dec; 223(6):898.e1-898.e16. PubMed ID: 32585222
[TBL] [Abstract][Full Text] [Related]
40. Phytoestrogens for vasomotor menopausal symptoms.
Lethaby AE; Brown J; Marjoribanks J; Kronenberg F; Roberts H; Eden J
Cochrane Database Syst Rev; 2007 Oct; (4):CD001395. PubMed ID: 17943751
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
